Laurus Labs (LAURUS)’s Annual Report Analysis indicates a sharp improvement in
ROE, led by a strong head-start in Finished dosage forms (FDF), improving operating
profit, and a reduced interest rate, the brokerages have upgraded their target as well;
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在
使用條款閱讀更多資訊。